FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365138001> ?p ?o ?g. }

• W4365138001 endingPage "821" @default.
• W4365138001 startingPage "810" @default.
• W4365138001 abstract "Mutations in the human leucine rich repeat protein kinase-2 (LRRK2) create risk factors for Parkinson's disease, and pathological functions of LRRK2 are often correlated with aberrant kinase activity. Past research has focused on developing selective LRRK2 kinase inhibitors. In this study, we combined enhanced sampling simulations with HDX-MS to characterize the inhibitor-induced dynamic changes and the allosteric communications within the C-terminal domains of LRRK2, LRRK2RCKW. We find that the binding of MLi-2 (a type I kinase inhibitor) stabilizes a closed kinase conformation and reduces the global dynamics of LRRK2RCKW, leading to a more compact LRRK2RCKW structure. In contrast, the binding of Rebastinib (a type II kinase inhibitor) stabilizes an open kinase conformation, which promotes a more extended LRRK2RCKW structure. By probing the distinct effects of the type I and type II inhibitors, key interdomain interactions are found to regulate the communication between the kinase domain and the GTPase domain. The intermediate states revealed in our simulations facilitate the efforts toward in silico design of allosteric modulators that control LRRK2 conformations and potentially mediate the oligomeric states of LRRK2 and its interactions with other proteins." @default.
• W4365138001 created "2023-04-13" @default.
• W4365138001 creator A5009462434 @default.
• W4365138001 creator A5010230212 @default.
• W4365138001 creator A5034553779 @default.
• W4365138001 creator A5038777732 @default.
• W4365138001 creator A5040726630 @default.
• W4365138001 creator A5045962448 @default.
• W4365138001 creator A5090504058 @default.
• W4365138001 date "2023-04-12" @default.
• W4365138001 modified "2023-10-05" @default.
• W4365138001 title "Capturing Differences in the Regulation of LRRK2 Dynamics and Conformational States by Small Molecule Kinase Inhibitors" @default.
• W4365138001 cites W1178456644 @default.
• W4365138001 cites W1866162007 @default.
• W4365138001 cites W1891334654 @default.
• W4365138001 cites W1966262422 @default.
• W4365138001 cites W1967900265 @default.
• W4365138001 cites W1970103851 @default.
• W4365138001 cites W1975734016 @default.
• W4365138001 cites W1992365739 @default.
• W4365138001 cites W2004536040 @default.
• W4365138001 cites W2024726841 @default.
• W4365138001 cites W2031345305 @default.
• W4365138001 cites W2052420692 @default.
• W4365138001 cites W2052826095 @default.
• W4365138001 cites W2063127941 @default.
• W4365138001 cites W2065283382 @default.
• W4365138001 cites W2067405360 @default.
• W4365138001 cites W2090763498 @default.
• W4365138001 cites W2099111846 @default.
• W4365138001 cites W2100894616 @default.
• W4365138001 cites W2112286366 @default.
• W4365138001 cites W2136216054 @default.
• W4365138001 cites W2520646257 @default.
• W4365138001 cites W2593373447 @default.
• W4365138001 cites W2594492616 @default.
• W4365138001 cites W2598412882 @default.
• W4365138001 cites W2602958770 @default.
• W4365138001 cites W2609407882 @default.
• W4365138001 cites W2742044901 @default.
• W4365138001 cites W2745510155 @default.
• W4365138001 cites W2763029597 @default.
• W4365138001 cites W2791662743 @default.
• W4365138001 cites W2795590254 @default.
• W4365138001 cites W2922340164 @default.
• W4365138001 cites W2960012086 @default.
• W4365138001 cites W2973230134 @default.
• W4365138001 cites W2979422598 @default.
• W4365138001 cites W3015224068 @default.
• W4365138001 cites W3034990744 @default.
• W4365138001 cites W3068292362 @default.
• W4365138001 cites W3092460711 @default.
• W4365138001 cites W3165747523 @default.
• W4365138001 cites W3171048111 @default.
• W4365138001 cites W3174998064 @default.
• W4365138001 cites W3187544615 @default.
• W4365138001 cites W3200383688 @default.
• W4365138001 cites W3200681264 @default.
• W4365138001 cites W4200284610 @default.
• W4365138001 cites W4213050708 @default.
• W4365138001 cites W4213439607 @default.
• W4365138001 cites W4280631615 @default.
• W4365138001 doi "https://doi.org/10.1021/acschembio.2c00868" @default.
• W4365138001 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37043829" @default.
• W4365138001 hasPublicationYear "2023" @default.
• W4365138001 type Work @default.
• W4365138001 citedByCount "6" @default.
• W4365138001 countsByYear W43651380012023 @default.
• W4365138001 crossrefType "journal-article" @default.
• W4365138001 hasAuthorship W4365138001A5009462434 @default.
• W4365138001 hasAuthorship W4365138001A5010230212 @default.
• W4365138001 hasAuthorship W4365138001A5034553779 @default.
• W4365138001 hasAuthorship W4365138001A5038777732 @default.
• W4365138001 hasAuthorship W4365138001A5040726630 @default.
• W4365138001 hasAuthorship W4365138001A5045962448 @default.
• W4365138001 hasAuthorship W4365138001A5090504058 @default.
• W4365138001 hasBestOaLocation W43651380011 @default.
• W4365138001 hasConcept C104317684 @default.
• W4365138001 hasConcept C12554922 @default.
• W4365138001 hasConcept C143065580 @default.
• W4365138001 hasConcept C166342909 @default.
• W4365138001 hasConcept C181199279 @default.
• W4365138001 hasConcept C184235292 @default.
• W4365138001 hasConcept C185592680 @default.
• W4365138001 hasConcept C2775905019 @default.
• W4365138001 hasConcept C2780427247 @default.
• W4365138001 hasConcept C32619005 @default.
• W4365138001 hasConcept C501734568 @default.
• W4365138001 hasConcept C55493867 @default.
• W4365138001 hasConcept C59143045 @default.
• W4365138001 hasConcept C70721500 @default.
• W4365138001 hasConcept C82495950 @default.
• W4365138001 hasConcept C86803240 @default.
• W4365138001 hasConcept C95444343 @default.
• W4365138001 hasConcept C97029542 @default.
• W4365138001 hasConceptScore W4365138001C104317684 @default.
• W4365138001 hasConceptScore W4365138001C12554922 @default.
• W4365138001 hasConceptScore W4365138001C143065580 @default.

• next